Ignite Creation Date:
2024-05-05 @ 11:53 PM
Last Modification Date:
2024-10-26 @ 10:41 AM
Study NCT ID:
NCT01440595
Status:
TERMINATED
Last Update Posted:
2024-05-22
First Post:
2011-09-22
Brief Title:
Grazoprevir MK-5172 With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C MK-5172-012
Sponsor:
Merck Sharp Dohme LLC
Organization:
Merck Sharp Dohme LLC
Study Overview
Official Title:
A Randomized Partially Double-Blind Active-Controlled Dose-Ranging Estimation Study to Evaluate the Safety Tolerability and Efficacy of Different Regimens of MK-5172 When Administered Concomitantly With Pegylated-Interferon and Ribavirin in Treatment-Naive Patients With Chronic Genotype 2 or 3 Hepatitis C Virus Infection
Status:
TERMINATED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Preliminary results of MK-5172 PN003 NCT01353911 suggested a possible dose relationship to elevated transaminase levels in treatment with grazoprevir
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the safety tolerability and antiviral activity of grazoprevir MK-5172 when administered concomitantly with peg-interferon alfa-2b Peg-IFN and ribavirin RBV to treatment-naïve participants with chronic genotype 2 GT2 or genotype 3 GT3 hepatitis C virus HCV infections
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2011-003299-36 | EUDRACT_NUMBER | None | None |